Intuitive Surgical (ISRG)

They have both outperformed the broader equity market over the long run.

What happened? A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senat...

Selling surgical robots is not the largest source of Intuitive Surgical's revenue.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

The market might be underestimating these companies’ prospects.

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

Ark Invest bought into some market laggards on Wednesday.

Intuitive Surgical posted Q3 margin impairments from a legal settlement and pricing changes, but revenue grew 21.5%, guidance firmed, and analysts and institutions remain bullish on ISRG.

Resolving a major litigation settlement while expanding into cost-sensitive outpatient centers positions the company for sustained procedure growth.

Revenue hit $3.05 billion as procedure volumes surged and system placements accelerated.

Medical technology company Intuitive Surgical (NASDAQ:ISRG) beat Wall Street’s revenue expectations in Q3 2026, with sales up 21.7% year on year to $3.05 bil...

Intuitive Surgical (NASDAQ:ISRG) reported third-quarter 2026 revenue growth of 22% to just over $3 billion as procedure growth, system placements and adoption of newer platforms supported results. The company said 84% of quarterly revenue was recurring revenue, while non-GAAP earnings per share rose

Medical technology company Intuitive Surgical (NASDAQ:ISRG) beat Wall Street’s revenue expectations in Q3 2026, with sales up 21.7% year on year to $3.05 bil...

Robotic surgery is growing, procedures are climbing, and da Vinci 5 is rolling out. Is Intuitive Surgical's premium valuation worth paying?

Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be announcing earnings results this Tuesday after market hours. Here’s what investors should...

I'm a shareholder, myself, with no plans to sell.

Johnson & Johnson posted Q3 revenue growth of 5.9% to $25.4 billion, raised guidance, and gained analyst support as its OTTAVA surgical system and talc settlement shape its long-term outlook.

Abbott trades at a 18x forward P/E with $7.4B in free cash flow, while Intuitive Surgical commands a 39x multiple backed by zero debt and 20% revenue growth.